BOSTON, MA and WASHINGTON, DC–(Marketwire – October 19, 2010) –  Large companies forced to scale back healthcare coverage. Employees left stranded, picking up the difference. The stakes for American business are at an all-time high. Unmanaged, preventable healthcare costs are one of the largest drains on corporate income statements. But, employers have the power to turn the tables. They play a vital role in encouraging healthy behaviors amongst their workforce and must create a workplace culture of prevention to avoid a profitability crisis of epic proportions. 

That’s the message delivered to major employers by Chris Boyce, CEO of Virgin HealthMiles at the 2010 Integrated Care Summit in Washington, DC on October 15. Virgin HealthMiles is a leading provider of employee health and productivity programs that pay people to get active. More about Boyce’s and other experts’ perspectives on creating a workplace culture of prevention and insights on employee health trends can be found on Virgin HealthMiles’ new blog, www.theuprisingblog.com.

More than 75 percent of today’s healthcare costs stem from preventable, chronic diseases that are largely driven by our own personal health behaviors. And while companies pay for employee healthcare coverage at amounts rising more than 10 percent each year, said Boyce, they’re also absorbing 70-80 percent of these cost increases. At the same time, employees are incurring higher out-of-pocket costs and larger shares of their premiums. The Kaiser Family Foundation found the average family coverage premium increased 131 percent from 1999-2009, while worker contributions increased 128 percent.

Employers can no longer shoulder this burden alone. With the US median wage at about $43,000 per year, employees can’t bear much more, either. The good news? Companies can take action and impact the prevalence of lifestyle-related diseases and their resulting medical and productivity costs by getting employees to make healthy behavior changes.

Boyce said many employers are proactively managing these costs by creating a workplace culture of prevention and getting employees to become more physically active. Yet, more employers could, and should do more. According to a recent PricewaterhouseCoopers survey, 94 percent of employers believe they could do a better job in supporting their employees’ health improvement efforts. What’s more, an April 2010 study by Virgin HealthMiles showed nearly 85 percent of the 1,926 employee respondents believe an employer has a responsibility to take a leadership role in encouraging and promoting wellness in the workplace.  

“Chronic diseases drain our nation’s health, our businesses, and our economy. It’s imperative we focus on prevention and keeping people healthy so we can avoid the rising demand for costly healthcare services,” said Boyce. “Focusing on prevention promotes personal responsibility and links lifestyle choices to good health. It also allows companies to ensure their interests are aligned with those of their employees so they can productively work together to drive down lifestyle-related healthcare costs.”

Savvy companies across the country are using innovative, technology-based employee wellness incentive programs to build this culture of prevention, reported Boyce. These programs go beyond traditional wellness programs by motivating entire employee populations to participate through meaningful and affordable incentives. The programs are measurable, and help both companies and workers quantifiably track progress and program impact. And they’re manageable, so organizations can integrate various, splintered wellness efforts and incentives structures while aligning incentives for actual performance. When employed, such strategies fuel long-term healthy behavior change and healthcare cost reductions for employees and companies alike.

About Virgin HealthMiles
Virgin HealthMiles provides employee health programs that pay people to get active. The company’s Pay-for-Prevention™ approach, based on physical activity and healthy lifestyle change, attracts an average of 40 percent of employees who participate, which helps organizations reduce medical costs and improve employee productivity and satisfaction. The program is offered by employers, government entities, and insurers. Over 120 industry leaders representing more than 500,000 employees across the U.S., including American Diabetes Association, Intuit, MWV, OhioHealth, Ochsner Health System, Protective Life, SunGard, SunTrust, and Timberland have selected Virgin HealthMiles’ award-winning program for their employees. The company is a member of Sir Richard Branson’s Virgin Group. For more information, visit www.virginhealthmiles.com

Click here to see all recent news from this company

NATICK, MA–(Marketwire – October 19, 2010) –  The Healthcare IT Solutions Exchange (HITSE) announces its slate of speakers and updates on tracks to be featured at its healthcare IT conference, HITSE New England 2010, to be held October 26 and 27 at the Doubletree Hotel, Westborough, MA. This is the first in a series of conferences to provide healthcare IT professionals with continuing education, purchase planning assistance and peer networking around issues facing hospitals and healthcare systems. 

HITSE New England‘s speakers include healthcare industry experts and CIOs, who will discuss topics related to the four conference tracks:

• Computerized Physician Order Entry (CPOE);
• Meaningful Use;
• Migrating to MEDITECH 6.0; and
• Revenue Cycle Management. 

Each track includes two speaker presentations, one panel discussion and an interactive session with vendors responding to issues raised by the speakers and attendees. Issues such as interoperability, business continuance and workforce scheduling will be addressed and case studies, product demonstrations and participation in user group discussions will be offered.

Key presentations are scheduled featuring the following speakers:

• Ray Campbell, Executive Director and CEO, Massachusetts Health Data Consortium, provides information and updates on Meaningful Use; 
• Dr. Cupid Gascon, Medical Director of Emergency Services at Oswego Hospital, discusses CPOE: A Physician’s Perspective;
• Bill O’Toole, Founder of O’Toole Law Group, provides valuable insight on Contract Considerations for MEDITECH 6.0;
• Ron Kilmer, Patient Services Manager at Nathan Littauer Hospital, presents The Evolving Role of Case Management in the Revenue Cycle; and
• Chuck Duncan, CEO of Healthcare Revenue Strategies, shares his experience in Effective Revenue Cycle Management.

“By organizing the HITSE New England conference, we are trying to leverage the benefit of peer-to-peer interaction, particularly to the delivery of healthcare,” states Arthur Young, president of Interbit Data and one of the founding HITSE members. “Healthcare IT professionals will have the opportunity to share experiences and exchange information and best practices, as well as collaborate with vendors on implementing solutions.”

All members of the healthcare IT community can participate and benefit from HITSE, including CIOs, IT managers, IT department managers, IT staff and consultants, as well as IT vendors. Vendor exhibition and sponsor opportunities have already sold out for this conference, however vendors are welcome to register as conference attendees.

More information on HITSE New England conference registration can be found at http://www.hitse.org.

About Interbit Data
Founded in 1997 and named to the 2009 and 2010 Inc. 5000 list of America’s fastest growing companies, Interbit Data helps healthcare organizations deliver better, more consistent patient care with secure, reliable and cost-effective software solutions that improve operational efficiency. The company’s information distribution products deliver information securely over the Internet in multiple formats, such as fax, print, email, encrypted file or HL7 message format, and integrate it easily into physicians’ practice EMRs. Interbit Data’s business continuance products give healthcare providers continuous access to patient data in the event of a network or system outage. Interbit Data products are used by more than 650 MEDITECH^® customers worldwide. For more information about Interbit Data and its NetSolutions products, visit the company Website at www.interbitdata.com.

Click here to see all recent news from this company

COLUMBUS, OH–(Marketwire – October 19, 2010) –  Robert M. Honigberg, MD, MBA has joined the innovative Quantum Health as the company’s new consulting Medical and Healthcare Strategy Director.

Dr. Honigberg is also the current Chief Medical Officer of URAC (Utilization Review Accreditation Commission) in Washington, D.C., and is a steering committee member of the Aspen Health Stewardship Project and on the Board of Directors of the Center for International Health. 

As Quantum Health’s Medical and Healthcare Strategy Director, Dr. Honigberg will evaluate strategic opportunities and review Quantum Health’s programs to ensure patient safety and promotion of healthcare quality as well as provide guidance on reporting and publication of data. “As a physician focused on quality and innovative solutions, I am especially attracted to Quantum Health’s approach and creation of ‘Virtual Medical Homes’ to both improve quality and reduce waste and inefficiencies. I think it’s the right approach and their track record proves the efficacy,” said Dr. Honigberg.

“Healthcare is undergoing seismic change in the United States; adding Bob to our team strengthens our ability to grow with consistent and sustainable focus on quality. His unique background will also contribute to the already very positive relationships we have with providers across the country,” remarks Kara Trott, founder and CEO of Quantum Health. “His overall thought-leadership and influence will only strengthen our ability to continue to help make healthcare more effective for physicians and patients alike.”

Dr. Honigberg was recently the Chief Medical Officer, Global Medical Affairs and Clinical Strategy, for GE Healthcare’s $17 billion portfolio, which is a unit of the General Electric Company that provides a broad range of products and services to better diagnose and treat cancer, heart disease, neurological disease and other medical conditions earlier. Dr. Honigberg was responsible for strategies and operations related to clinical research and trials, the protection of patient safety, and medical communication to providers and governments. Before joining GE Healthcare, he was the Vice President, Worldwide Medical Affairs and Chief Medical Officer, at Ethicon Endo-Surgery, a Johnson & Johnson Operating Company, for seven years. He undertook his internship and residency in surgery at Montefiore Hospital and the Albert Einstein College of Medicine in New York City. His educational background includes a B.A. in Economics from Duke University, an MD from the Feinberg School of Medicine at Northwestern University, and an MBA from the Kellogg School of Management at Northwestern University. 

ABOUT QUANTUM HEALTH
Quantum Health is an award-winning and fundamentally different health care company headquartered in Columbus, Ohio, serving employers nationally.

Quantum Health guarantees their clients a 5-8% reduction in total claims spend. By reorganizing benefits delivery and creating a “virtual medical home” for each member, Quantum Health maximizes each service opportunity to intercept patients when they have a problem to solve or questions about their benefits or healthcare. Real time, informed involvement allows our Care Coordinators to help patients, their families, and their physicians to work together to ensure proper care, eliminating redundant, delayed and questionable care — literally driving unnecessary medical events and cost out of the system. All with a 100% guarantee.

HONG KONG–(Marketwire – October 19, 2010) –  First China Pharmaceutical Group, Inc. (OTCBB: FCPG) (“First China” or the “Company”) is pleased to announce it has recently signed agreements to distribute medicinal and pharmaceutical products to three district hospitals in Yunnan Province, thereby dramatically increasing its regional market share.

The agreement comes, in part, as a result of a proposal put forward in 2009 by the Ministry of Health during the National Health Conference that public hospitals should gradually phase out the existing 15% medicines and pharmaceutical products “cost plus” pricing system within 3 years. The government also advised that medical institutions should centralize their procurement and distribution of drug and pharmacare products.

These new guidelines identified that the previous system maintained high prices and commissions which have been deemed unsustainable and that these institutions should move towards agreements with large scale pharmaceutical distributors. This new methodology has been welcomed and is increasingly becoming popular as many leading hospitals and clinics move to this new system of procurement.

This news has been welcomed at First China and the results are just now coming to fruition with these new contracts now in place with the Yunnan No. 1 Peoples Hospital as well as the Kunming Yanan and Lin Cang Peoples Hospitals. The Company is perfectly positioned to take advantage of this Government approved purchasing directive and stands ready to be catapulted into the forefront of this rapidly growing market segment.

First China’s combination of bulk purchasing, low prices and growing variety of product lines (both Chinese and Western) complements its high capacity supply chain and B2B operating system all of which fully utilizes and exploits the benefits of their exclusive government issued internet ordering and distribution license. As a result, the Company is daily increasing its differentiation from the rest of the competition in this region of over 45 million inhabitants. 

Currently any hospital or clinic in Yunnan Province can easily sign up to procure the medicines they need from First China, enjoying instant response, rapid fulfillment and secure services combined with excellent price points, allowing those institutions to recover increased margins while offering lower retail pricing in many instances.

First China Pharmaceutical Group plans to continue the growth of the company from its current position as a provider of approximately 5,000 drugs to more than 4,700 pharmacies, hospitals and clinics in China’s Yunnan Province. The Company anticipates its business model will change to leverage the efficiencies of internet ordering and fulfillment and intends to rapidly expand its capacity to approximately 30,000 products. It is estimated that a broader product line will ensure customers will be able to order 80% to 90% of their product needs directly from the Company.

The Definitive Agreement contains customary representation and warranties, covenants and indemnification provisions and conditions. Details of the company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About First China Pharmaceutical Group, Inc. (OTCBB: FCPG)
First China Pharmaceutical Group, Inc. aims to develop a high growth pharmaceutical distribution company generating significant revenue from the sale of healthcare products in China. As part of its business strategy, the Company has acquired the assets of Kun Ming Xin Yuan Tang Pharmacies Co. Ltd. (XYT), which includes a strategic advantage over its competitors as it is the only pharmaceutical distribution company in Yunnan Province that has obtained government approval to fulfill orders over the internet. First China Pharmaceutical Group plans to continue the rapid growth of the company from its current position as a provider of approximately 5,000 drugs to more than 4,700 pharmacies, hospitals and clinics in China’s Yunnan Province. For more information visit: www.firstchinapharma.com

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, regulatory incentives, the development of new business opportunities, and projected costs, revenue, profits and results operations. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD
First China Pharmaceutical Group, Inc.
————————————————-
Zhen Jiang Wang
Chairman and CEO

Click here to see all recent news from this company

LOS ANGELES, CA–(Marketwire – October 19, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (MMR) today announced that it has entered into an agreement with Chartis to offer its energy casualty clients a suite of secure, online products that will allow their employees to manage critical, sensitive information such as medical, financial and vital records. The Chartis insurers will offer this service as part of their Global Marine and Energy workers’ compensation policies. The program will be offered to policyholders starting later this month at www.chartisinsurance.com/mmr.

Powered by MMRGlobal using its MyMedicalRecords technology (www.mmrvideos.com), clients’ employees and their families will be able to store and manage their medical records and personal health information, including lab reports, X-rays and scanned images, wellness tools and family health history, in a secure, encrypted Web-based application that can be accessed 24/7 from anywhere in the world using the Internet. The program will also allow for storage of other important documents, such as passports, deeds of trust and wills.

“At a time when the world is spending hundreds of billions of dollars on health information technology, I am proud that MMRGlobal is working with a company that is first to deploy personal health records in their industry,” said Robert H. Lorsch, Chairman and CEO of MMRGlobal. “As part of the program launch, MMR produced a training video featuring MMRGlobal Advisory Board member, Astronaut Buzz Aldrin, who joins Tom Morelli, President of the Global Marine and Energy Casualty Division of Chartis, to demonstrate how to utilize MMR’s proprietary personal health record products to employees and agents.”

“As part of an ongoing commitment to support our clients, we will expand our offerings as their needs evolve. We are very excited to offer our energy business clients this new benefit,” said Mr. Morelli.

In addition to a comprehensive file management system, each personal health record will feature a separate emergency log-in that will allow first responders and other medical personnel to access potentially life-saving information such as blood type, medications and allergies.

For more information on the electronic personal health records program, please visit www.mymedicalrecords.com.

About Chartis

Chartis is a world leading property-casualty and general insurance organization serving more than 45 million clients in over 160 countries and jurisdictions. With a 90-year history, one of the industry’s most extensive ranges of products and services, deep claims expertise and excellent financial strength, Chartis enables its commercial and personal insurance clients alike to manage virtually any risk with confidence. Chartis is the marketing name for the worldwide property-casualty and general insurance operations of Chartis Inc. For additional information, please visit our website at http://www.chartisinsurance.com.

All products are written by insurance company subsidiaries or affiliates of Chartis Inc. Coverage may not be available in all jurisdictions and is subject to actual policy language. Non-insurance products and services may be provided by independent third parties. Certain coverage may be provided by a surplus lines insurer. Surplus lines insurers do not generally participate in state guaranty funds and insureds are therefore not protected by such funds.

About MMRGlobal

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (MMR), provides secure and easy-to-use online personal health records (PHRs) and electronic safe deposit box storage solutions that enable individuals and families to maintain and access all their medical records and other important documents anytime from anywhere in the world using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements, and some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue.” MMRGlobal, Inc. and Chartis disclaim any intent or obligation to update any forward-looking statements. These forward-looking statements are based on the reasonable expectations of both parties as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. The information discussed in this release is subject to various risks and uncertainties related to changes in MMRGlobal’s relationship with Chartis, the parties’ business prospects, results of operations or financial condition, government regulations and such other risks and uncertainties as detailed from time to time in MMRGlobal’s and Chartis’ public filings with the U.S. Securities and Exchange Commission.

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – October 19, 2010) –  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) and its exclusive India-based distribution partner Jaiva Technologies, Inc. (JTI) and Jaiva’s Indian subsidiary Gaur Diagno, Pvt Ltd (GDL) announced today the launch of a cancer education and screening program in India — a key international market where GDL is actively commercializing RPC’s Onko-Sure® in vitro diagnostic (IVD) cancer test. The goal of the program is to drive public education; raise market awareness; and offer Onko-Sure® as a commercialized cancer screening test that can potentially help stem the rising cancer epidemic in India.

According to the Cancer Foundation of India, cancer impacts up to 2.5 million people in India annually and the fight against cancer — in both the public and private healthcare sectors — is largely restricted to improving diagnostic and treatment facilities throughout the country. Because of this, it has become increasingly vital to enhance activities and programs that support cancer education and offer treatment options to potential and existing cancer patients. 

With the launch of its cancer education and screening program on behalf of RPC, GDL is taking an aggressive leadership role in India with two distinct launch strategies. The first comprises a widespread deployment of GDL’s mobile cancer screening laboratory units where Indian-based physicians and other medical staff travel to local towns to provide counseling and education, along with patient screening using RPC’s Onko-Sure® IVD cancer test. The second program is focused on Company collaboration with Indian government agencies to establish GDL-sponsored cancer screening and testing facilities directly on-site in government hospitals. Physician-referred general cancer screening will also be conducted at these hospitals and it is anticipated that RPC’s Onko-Sure® IVD cancer tests will be administered to patients contacted through the program. The goal of both strategies is to reduce the incidence of cancer in India, and through each program, patients will be provided with registered health cards that will track a patient’s health records for future reference and statistical analysis.

RPC’s projected Onko-Sure® IVD test kit purchase plan is focused primarily on the ramp-up of the government sponsored cancer testing program. RPC estimates test kit purchases to be approximately US$2 million in FY2011, and US$3 million in FY2012. These estimates are subject to change based on results of the 64-point questionnaire and these figures have the potential to increase if GDL’s results show more than 50% of the patients at high-risk when screened through the 64-point questionnaire.

According to Mr. Douglas MacLellan, Executive Chairman and CEO of RPC, “The introduction of GDL’s new cancer education and screening program in India is the next most important and major milestone in the commercialization of Onko-Sure® in India. GDL is taking a leadership role in providing a market with 2.5 million cancer patients with not only educational resources and support through this program, but also the potential of early disease detection and on-going monitoring though our USFDA approved Onko-Sure® IVD cancer test.”

According to Dr. Umesh Bhatia, CEO of JTI and GDL, “This government screening program is a breakthrough project and we believe a continuous and aggressive approach is necessary if we are to reduce the incidence of cancer in India. We anticipate this is just the beginning of additional large-scale screening programs we employ. GDL is committed to continuing all efforts to work with Indian government agencies with the ultimate goal of reducing cancer rates in this country.”

RPC’s Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test. For more information visit www.onko-sure.com.

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.Radient-Pharma.com.

About Jaiva Technologies and Gaur Diagno:
Jaiva Technologies, headquartered in Houston, TX, and subsidiary Gaur Diagno, headquartered in New Delhi, India, are working to develop and license novel products for life-threatening diseases. Through science and innovation the company aims to develop novel therapies that will significantly impact and extend the quality of life for patients. Part of the company’s effort is large-scale screening of populations that result in meaningful and epidemiological slow-down of life threatening diseases, such as cancer. For further information visit www.gaurdiagno.com.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

INDIANAPOLIS, IN–(Marketwire – October 19, 2010) –  ImmuneWorks, Inc. today announced the initiation of its Phase I clinical trial in patients suffering from idiopathic pulmonary fibrosis (IPF), a serious lung disease. The clinical trial will move the biotech company one step closer to commercialization of its lead IPF treatment compound.

Eight leading academic research universities will conduct the IPF clinical trial: Indiana University, Medical University of South Carolina, Ohio State University, University of Alabama-Birmingham, University of Chicago, University of Louisville, University of Michigan and University of Vermont.

“We are pleased to move forward into clinical investigation of our purified Type V collagen solution in patients suffering from IPF,” said ImmuneWorks Chief Scientific Officer David S. Wilkes, M.D. “This clinical trial is important to study the safety of this naturally derived protein and investigate its ability to influence the ongoing immune response in IPF patients.”

To promote the clinical trial and recruit participants across the eight cities, ImmuneWorks partnered with Indianapolis-based Synergy Marketing Group to develop a new website and conduct search engine optimization (SEO) to reach IPF patients and their physicians, friends and family members in Indianapolis; Chicago; Louisville, Ky.; Ann Arbor, Mich.; Birmingham, Ala.; Charleston, S.C.; Burlington, Vt.; and Columbus, Ohio. The new website is www.ImmuneWorks.com.

ImmuneWorks has been conducting research and development of treatments for serious autoimmune lung diseases for the last five years. Over that time, the company attracted the attention of several key investors, raising nearly $4 million. This funding came from groups including Indiana’s 21^st Century Research & Technology Fund, BioCrossroads’ Indiana Seed Fund and the IU Medical Group Foundation.

IPF is a devastating lung disease that is progressive and generally fatal. An estimated 128,000 persons in the United States suffer from IPF, with 48,000 new persons diagnosed annually and 40,000 patients dying from the disease each year (source: Coalition for Pulmonary Fibrosis). The number of deaths annually is the same as breast cancer and greater than other cancers such as multiple myeloma. Currently no FDA-approved medicines exist for IPF in the United States or Europe.

About ImmuneWorks
Headquartered in Indianapolis, ImmuneWorks was formed in 2006 to develop and commercialize treatments for serious autoimmune diseases of the lung. Led by founders David Wilkes, MD; Michael Klemsz, PhD; Ronald Meeusen, PhD; and President and CEO Wade Lange, the company has made pioneering scientific discoveries that ImmuneWorks is developing as novel therapies and diagnostic products for idiopathic pulmonary fibrosis (IPF) and lung transplantation. In November 2009, the U.S. Food and Drug Administration (FDA) granted orphan drug exclusivity to ImmuneWorks’ lead compound, IW001, a purified bovine Type V Collagen oral solution. In June 2010, the U.S. FDA granted ImmuneWorks approval to begin clinical trials on the compound. Now, in collaboration with Lung Rx, LLC, a wholly-owned subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), ImmuneWorks is conducting clinical trials among IPF patients to test the effects of its new drug candidate. For more information about the company, visit the new website at www.ImmuneWorks.com.

MARKHAM, ONTARIO–(Marketwire – Oct. 19, 2010) – Extendicare Real Estate Investment Trust (“Extendicare REIT” or “Extendicare”) (TSX:EXE.UN) today announced it will hold a conference call and live audio webcast on Friday, November 5, 2010 at 10:00 a.m. (ET) to discuss financial results for the third quarter ended September 30, 2010.

Following the issuance of the news release on November 4, 2010, Extendicare will post a copy, along with an update of the supplemental information package, on its website www.extendicare.com under the investors/financial reports section.

The call will be hosted by Tim Lukenda, President and Chief Executive Officer; Doug Harris, Senior Vice President and Chief Financial Officer, and Paul Tuttle, President of Canadian Operations. Following management’s presentation, there will be a question and answer session for analysts and institutional investors.

To participate in the November 5, 2010, conference call, please dial 1-866-696-5910 or 416-340-2217 followed by the passcode 8528242#. The conference call will also be accessible via webcast at www.extendicare.com under the investors/presentations & webcasts section. A replay of the call will be available approximately two hours after completion of the live call until midnight on November 19, 2010. To access the rebroadcast dial 1-800-408-3053 or 416-695-5800, followed by the passcode 1846353#.

About Us

Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,800 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 263 senior care centers in North America have capacity for approximately 29,200 residents. Extendicare REIT is a specified investment flow-through trust (SIFT) that has been subject to the SIFT tax since January 1, 2007.

IRVINGTON, NY–(Marketwire – October 19, 2010) –  MELA Sciences, Inc. (NASDAQ: MELA) today announced that the results of the company’s MelaFind^® pivotal trial and pilot reader study have been published in the online edition of the journal Archives of Dermatology. The paper will appear in the February 2011 print edition of the journal.

“We are extremely pleased to see the results of the MelaFind^® pivotal trial reviewed by outside dermatology experts and published in this prestigious medical journal in the field of dermatology,” said Joseph V. Gulfo, MD, President and CEO of MELA Sciences. “We remain diligently focused on preparing for the November 18^th panel meeting where these data will be presented to and discussed with the Food and Drug Administration’s advisors.”

The paper shows that MelaFind’s performance satisfied all primary and secondary sensitivity and specificity endpoints, as defined by the study protocol and a Protocol Agreement between MELA Sciences and the FDA. The Protocol Agreement calls for 95% lower confidence bound on sensitivity to be greater than 95% and for MelaFind^® to be more specific than the study physicians at a p-value of less than 0.05. Since the measured values of sensitivity were very high, the “exact mid-P” statistical method was used to compute the 95% lower confidence bound. Specificity endpoints were based on relative performance of MelaFind^® and investigators, with significance established at p-value less than 0.05.

In order to generate a comparison with dermatologists’ biopsy sensitivity to melanoma, MELA Sciences conducted a parallel pilot readers’ study with 39 other dermatologists who were blinded to the study results. Importantly, the average biopsy sensitivity of the readers was only 80%, and the inter-reader variability was high.

“The pilot reader study found that dermatologists do miss early melanomas,” study author Kenneth Gross, MD, said. “Only 20% of the melanomas in the pilot reader study would have been biopsied by all readers and different readers missed different melanomas. Thus, even though all lesions in the clinical trial were biopsied by the examining dermatologists, many of the melanomas would not have been biopsied by other dermatologists, underscoring the need for an objective tool to aid in the decision to biopsy. We believe that the results of the pivotal trial and the pilot reader study underscore the clinical utility of MelaFind^® as an objective tool to aid clinicians in the detection of early melanoma.”

About MELA Sciences

MELA Sciences is a medical technology company focused on developing MelaFind^®. MelaFind^® is a non-invasive and objective multi-spectral computer vision system designed to aid physicians in the detection of early melanoma from among clinically atypical (those having one or more clinical or historical characteristics of melanoma, such as asymmetry, border irregularity, color variegation, diameter greater than 6 millimeters, evolving, patient concern, regression, and ugly duckling) cutaneous pigmented lesions that are non-ulcerated, not bleeding, and less than 2.2 centimeters in diameter, when a physician chooses to obtain additional information before making a final decision to biopsy to rule out melanoma.

The MelaFind^® Pre-Market Approval (PMA) application was filed with the U.S. Food and Drug Administration (FDA) in June 2009 and is currently under review at the FDA. MELA Sciences cannot predict either the timing of the FDA’s decision on the PMA application or the outcome. FDA approval is required prior to marketing MelaFind^® in the United States.

For more information on MELA Sciences, visit www.melasciences.com.

Safe Harbor

This press release includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as “expects,” “contemplates,” “anticipates,” “plans,” “intends,” “believes” and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to economic, business, competitive, market and regulatory factors.

PLEASANTON, CA–(Marketwire – October 19, 2010) –  Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), today announced the launch of its new Onboarding solution for the extended enterprise. With the new solution, Callidus now enables businesses to target, communicate with, and onboard sales professionals and independent channel partners as part of a comprehensive sales talent lifecycle management solution. The Onboarding solution has already been successfully implemented at one of the nation’s largest providers of healthcare programs.

“The sales professional is the principal driver of top-line business performance and one of the most costly hires businesses make,” said Leslie Stretch, president and CEO, Callidus Software. “The Callidus Onboarding solution is an integral component of managing the sales talent lifecycle to optimize on business goal execution. Companies with large independent partner networks in particular require a solution to seamlessly onboard new producers and drive sales velocity. The new solution automates each step of agent and producer deployment, accelerating recruiting, licensing, contracting, and field communications to enable companies to eliminate the bottlenecks that can threaten critical sales capacity targets, and control the costs of doing business with large producer volumes. At the same time, through built-in background checking and accreditation processing and tracking, the solution manages the risk of new appointments for our customers, enabling them to focus on driving revenue and long-term sales growth.”

By integrating the new Onboarding solution with its SPM suite, Callidus extends its footprint to provide the most comprehensive offering of sales talent lifecycle management solutions in the market today. The new solution leverages Callidus’ Business Process Management platform, adds sales professional and channel partner marketing and targeting, communications, and onboarding support to the suite’s capabilities to deliver a comprehensive operations platform that includes recruiting, licensing and appointing, goal setting, pay for performance, and coaching and training.

Key features of the solution include:

• Integrated agent marketing and communications for recruiting and capturing greater channel mindshare
• Flexible workflow platform that can easily be customized to meet a wide range of onboarding process configuration requirements
• Comprehensive electronic signature tracking
• Real-time verification of sales and agent data for background checking and accreditation requirements, including seamless integration with third-party registries and services
• Integrated with single repository for storing all agent demographics and contracts throughout onboarding and appointing
• Support for self-service portal for all field information, forms, and reports
• Full integration with the Callidus SPM suite for channel management, compensation management, and reporting and analytics

For more information on Callidus’ new Onboarding solution, click here.

“The needs of the selling network are fundamentally unique,” said Lorna Heynike, senior vice president, marketing at Callidus Software, commenting on the launch. “Sales lifecycle management, emerging from the discipline of sales performance management, is experiencing dramatic growth as more businesses make a strategic investment in their sales talent to drive top-line results. Callidus’ SPM suite makes it possible for businesses to significantly increase the likelihood for success in meeting top-line goals by driving goal execution throughout the sales force and channel network. Our new Onboarding solution strengthens our position as the leader in this very important market.”

Callidus Software’s award-winning solutions manage the entire sales lifecycle from onboarding, to incentives and rewards, to talent development, while providing visibility into sales operations and financial performance. This gives customers the ability to align their sales force and channels with their top business goals to consistently and reliably execute on target results. The software is used by leading companies in a broad range of verticals including high-tech, telecommunications, banking, insurance, and pharmaceuticals. Since its inception nearly 15 years ago, the company has evolved into the most experienced, proven, and reliable SPM vendor in the marketplace. Callidus Software manages over $50 billion in incentives and compensation for more than two million payees in over 140 countries.

About Callidus Software®
Callidus Software (NASDAQ: CALD) is the market and technology leader in Sales Performance Management (SPM). Callidus customers gain a competitive advantage by maximizing sales cost efficiencies and driving improvements in sales effectiveness. Our award-winning Software-as-a-Service (SaaS) applications set the standard for performance management of a company’s sales force and channel partners. Over 2 million employees and channel partners have their performance managed by Callidus Software. For more information, please visit www.callidussoftware.com

©1997-2010 Callidus Software Inc. All rights reserved. Callidus Software, the Callidus Software logo, and TrueComp Manager are trademarks, service marks, or registered trademarks of Callidus Software Inc. in the United States and other countries. All other brand, service or product names are trademarks or registered trademarks of their respective companies or owners.

Click here to see all recent news from this company

NASHVILLE, TN–(Marketwire – October 18, 2010) –  In conjunction with Vanguard Health Systems, Inc.’s 2011 First Quarter Earnings press release, you are invited to listen to its conference call that will be broadcast live over the Internet with senior management of Vanguard discussing the operating results.

WHAT:

Vanguard Health Systems, Inc.’s 2011 First Quarter Earnings Conference Call on the Web

WHEN: 

Tuesday, November 9, 2010 at 11:00 a.m. Eastern time

WHERE:

http://www.vanguardhealth.com or
http://www.visualwebcaster.com/event.asp?id=73288

HOW: 

Live over the Internet — Simply log on to the web at one of the addresses above. If you connect through www.vanguardhealth.com, select the “Latest News” link on the Investor Relations page.

Vanguard Health Systems, Inc. will release its 2011 first quarter operating results on Monday, November 8, 2010, after 4:00 p.m. Eastern time. The Company’s earnings press release will be posted under the “Latest News” link on the Investor Relations page of the Company’s web site www.vanguardhealth.com.

Vanguard Health Systems, Inc. owns and operates 18 acute care hospitals and complementary facilities and services in Chicago, Illinois; Phoenix, Arizona; San Antonio, Texas and Massachusetts.

If you are unable to participate during the live Webcast, the call will be archived on our web site www.vanguardhealth.com. To access the replay, click on the “Latest News” link on the Investor Relations page of our web site.

SAN JOSE, CA–(Marketwire – October 18, 2010) –  The Foundation for Health Coverage Education (FHCE)’s U.S. Uninsured Help Line 800-234-1317 received its 100,000th call last week, having experienced an uptick in queries from Americans about their options since the passage of health care reform six months ago. 

The professionally-trained call-center counselors have been inundated with callers seeking information about both low-cost government-sponsored and private health coverage options. Twenty-four hours a day, seven days a week in 190 languages, the Help Line counselors walk callers through their public and private options by distributing the FHCE’s 5-question Health Coverage Eligibility Quiz. The 100,000^th call is a milestone and indicator that FHCE and its resources are as important as ever.

“We actually expected a decrease in queries after the passage of the landmark health care legislation in the spring, but instead we’re finding the exact opposite,” said Ankeny Minoux, President of the FHCE. “The combination of individuals coming to the end of their COBRA coverage and those who are confused by the implementation steps of health care reform make up the bulk of those calling us for help.” 

The 24/7 U.S. Uninsured Help Line found a niche when it was created as a solution to the problematic statistic that one-third of uninsured Americans were eligible for government-sponsored health coverage, but not enrolled. The WellPoint Foundation has been the primary funder of the Help Line since its inception and continues to offer its exclusive support to advocate the importance of one-on-one live assistance when dealing with health coverage needs. The Call Center receives an average of 3,000 callers per month and acts as a consumer support system for the non-profit’s website, www.CoverageForAll.org. The website has likewise experienced a 20% increase in traffic in recent months, averaging 85,000 visitors per month. 

“In 2004, the WellPoint Foundation partnered with FHCE to establish the first-ever national Uninsured Hotline and we could not be more pleased that one hundred thousand individuals have utilized this important tool to understand their coverage options,” said Lance Chrisman, executive director of the WellPoint Foundation. “Our Foundation has provided more than $1.7 million in funding to keep the call center open 24/7 and we want to recognize FHCE for its continued commitment to the uninsured and on achieving this milestone.”

Five years ago, the pioneering non-profit put the entire U.S. health insurance system on CoverageForAll.org, including applications for 176 government-sponsored plans in all 50 states and the District of Columbia. As the first website of its kind to offer information on every public and private health coverage program in the country, CoverageForAll.org has already had more than 2 million visitors. Both the Call Center and website offer consumers the chance to ask questions about the complex health coverage system and many changes that will be occurring over the next few years. 

“When the government launched its own health care website in July, we figured it would pick up the slack of these queries,” said Minoux. “However, the government’s online function does not have a live counselor option. Along with the Call Center, CoverageForAll.org is configured differently and helps people actually figure out for which programs they qualify.”

The U.S. Uninsured Help Line 800-234-1317 will not slow down now that it has reached 100,000 callers. The landmark simply motivates the call center staff and non-profit to continue providing answers and guidance for the most complex health coverage questions.

About the Foundation for Health Coverage Education:

The Foundation for Health Coverage Education (FHCE) is a non-profit 501 (c) 3 organization with a mission to help simplify public and private health insurance eligibility information in order for more people to access coverage. In addition to its U.S. Uninsured Help Line (800) 234-1317 and website www.CoverageForAll.org, FHCE offers free consumer guides, such as the Health Care Options Matrix™, available for all 50 states.

About the WellPoint Foundation

The WellPoint Foundation is the philanthropic arm of WellPoint, Inc. and through charitable contributions and programs, the Foundation promotes the inherent commitment of WellPoint, Inc. to enhance the health and well-being of individuals and families in communities that WellPoint, Inc. and its affiliated health plans serve. The Foundation focuses its funding on strategic initiatives that address and provide innovative solutions to health care challenges, as well as promoting the Healthy Generations Program, a multi-generational initiative that targets specific disease states and medical conditions. These disease states and medical conditions include: prenatal care in the first trimester, low birth weight babies, cardiac morbidity rates, long term activities that decrease obesity and increase physical activity, diabetes prevalence in adult populations, adult pneumococcal and influenza vaccinations and smoking cessation. The Foundation also coordinates the company’s annual associate giving campaign and provides a 50 percent match of associates’ campaign pledges. To learn more about the WellPoint Foundation, please visit www.wellpointfoundation.org.

Click here to see all recent news from this company

BURBANK, CA–(Marketwire – October 18, 2010) –  Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that the company has completed the previously announced institutional transaction and has successfully been funded.

“We are pleased to announce the completion of this transaction, which was facilitated by Wharton Capital Partners, Ltd.,” stated Dean Janes, the company’s Chairman/CEO.

About Imaging3

Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.

VICTORIA, BRITISH COLUMBIA–(Marketwire – Oct. 18, 2010) – Following today’s trading halt by Investment Industry Regulatory Organization of Canada, CardioComm Solutions, Inc. (TSX VENTURE:EKG) (the “Company”) today confirmed that there is no material information pertaining to the Company which has not been disclosed.

About CardioComm Solutions, Inc.

CardioComm Solutions, Inc. (“CardioComm”) has been a consistent provider of ECG management software solutions in the English speaking world for the past 21 years. Its products are marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm is ISO 13485 certified and its products have been cleared for sale in the United States, Canada and the European Union. CardioComm’s competitive advantage is built upon 2 ECG patents, a unique FDA approved ECG analysis algorithm, a world class ECG (signal) viewer and a back-end ECG data management control system. CardioComm’s technology enables the recording, transfer, viewing, analyzing, reporting and storing of electrocardiograms (EKGs) over a global virtual healthcare network by physicians for the diagnosis and management of cardiac patients. CardioComm provides an ECG management solution which complements the majority of the world’s cardiac event monitors, including those intended for the home and tele-health market. CardioComm products are sold worldwide to hospitals, call centers and physicians offices through a combination of its external distribution network and its North American based sales team.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

Anatoly Langer, Chairman of the Board

BLUE BELL, PA–(Marketwire – October 18, 2010) –  PDS, a leading developer of human resource, benefits, recruiting and payroll systems, today announced that its Vista HRMS^® solution has been selected by Tender Touch Rehab Services, Inc. Based in Lakewood, N.J., Tender Touch will utilize Vista HRMS to manage HR, Payroll, Benefits, Recruiting, Self-service and Workflow for all of its employees located at various facilities throughout New York, New Jersey, Pennsylvania and Delaware.

“Our existing solution could handle some of our HR requirements, but was very limited in the areas of employee benefits, payroll, recruitment and reporting,” explained Ellie Hertz, HR representative at Tender Touch. “We needed an all-in-one solution that is accessible by all of our authorized staff members. With Vista HRMS’ ease of use, quick search capabilities and streamlined reporting, it is the kind of solution we have been dreaming about. Vista HRMS is the total package and it will enable us to focus our energies on more strategic initiatives to better serve our employees.”

“The data available to us was limited and the processes required to obtain the information we needed were cumbersome, causing more errors,” explained Amitai Levin, director of HR for Tender Touch. “In addition to the increase in accuracy we expect from Vista, we also believe that it will automate many of our processes, like approvals, notifications and benefits enrollment, allowing us to be more productive and provide our customers — the employees of Tender Touch — the best service possible.”

Tender Touch will be going live on Vista HRMS in late 2010. 

About PDS
In the HRMS software development business for more than 35 years, PDS is a provider of a feature-rich, completely integrated human resource, benefits administration, recruiting and payroll software application that enables organizations to focus on more strategic issues and less on administrative HR, benefits and payroll activities. In addition to core HRMS functionality, Vista HRMS^® offers self-service, English-language query tool and workflow automation. PDS also provides a full range of professional services to a wide variety of industries in the U.S. and in Canada. Founded in 1974, PDS is a privately-held company headquartered in Blue Bell, Pa. For more information on PDS or PDS’ Vista HRMS solution and services visit www.pdssoftware.com.

PDS and the PDS logo are registered trademarks and Vista is a trademark of Personnel Data Systems Inc. All other trademarks or registered trademarks are properties of their respective owners.

Click here to see all recent news from this company

ORLANDO, FL–(Marketwire – October 18, 2010) –  GARTNER SYMPOSIUM/ITxpo — Mezeo Software (www.mezeo.com), the leading provider of a deployable cloud storage platform, today announced Gluster (www.gluster.com), the leading provider of open source storage solutions, as a Mezeo Ready Solution Partner. As a Mezeo Ready solution, the Gluster Storage Platform enables organizations using a Mezeo-enabled private, hybrid or public storage cloud to realize the cost, scalability and performance benefits of the Gluster Storage Platform. The Gluster Storage Platform is an open source, scale-out storage solution that runs on commodity hardware and simplifies the task of managing unstructured data at cloud-scale. Storage resources are aggregated into a single pool under a global namespace providing virtual storage that scales elastically. 

“We welcome Gluster as a Mezeo Ready Partner, and believe that our customers will be excited about being able to deploy petabyte-scale storage in a Mezeo cloud in just a matter of minutes,” said Mezeo President and CEO Steve Lesem. “Gluster’s modular design makes it highly scalable and flexible, which is ideal for anyone needing to move large amounts of unstructured data into the cloud.”

“We share Mezeo’s interest in making it easy to deploy high-performance storage clouds that deliver on the promise of reduced costs and simplified manageability,” said Ben Golub, CEO at Gluster. “We deliver the ability to store large amounts of data as well as the ability to respond to dynamically changing demands and workloads. This is especially important for our customers in industries such as Web applications, digital media and healthcare.”

Launched in June, the Mezeo Ready Program provides an ecosystem for service providers, developers, cloud gateway providers and technology partners all focused on delivering Mezeo-enabled cloud storage solutions.

With Mezeo, enterprises can implement a secure, private cloud, and IT Service Providers can rapidly monetize a branded cloud storage service offering. Mezeo features end-to-end encryption, advanced file sharing and collaboration, content tagging and access anywhere with white label Web 2.0, native Windows® desktop, iPhone and BlackBerry® clients. Mezeo is easy to deploy, multi-tenant, and highly scalable and secure, with REST Web Services APIs for platform extensibility.

Mezeo will be showcasing the Mezeo Cloud Storage Platform in booth 1029 at the Gartner Symposium/ITxpo 2010, continuing through October 21^st in Orlando, Fla.

Follow Mezeo on Twitter: http://twitter.com/mezeo.

About Gartner Symposium/ITxpo
Gartner Symposium/ITxpo is the IT industry’s largest and most strategic conference, providing business leaders with a look at the future of IT. For more than 10,000 IT professionals from the world’s leading enterprises, Gartner’s annual Symposium/ITxpo events are key components of their annual planning efforts. Attendees rely on Gartner Symposium/ITxpo to gain insight into how their organizations can use technology to address business challenges and improve operational efficiency. 

About Gluster
Gluster delivers an open storage software platform focused on simplifying the task of storing and managing the explosive growth of unstructured data. Our scale-out storage platform runs on commodity hardware scaling out in building block fashion from a few terabytes to multiple petabytes to meet the most demanding capacity and performance needs at a fraction of the cost of traditional systems. Gluster Storage Platform uses a unified global namespace to virtualize disk and memory resources into a single shared pool that is centrally managed. Our scalable NAS solutions address the needs of traditional data centers, shared storage for virtual server environments, and both public and private storage clouds. Gluster Storage Platform is used in a wide range of industries including digital media delivery, healthcare, internet, energy, and biotech. Gluster is privately-held and headquartered in Milpitas, California. For more information, visit www.gluster.com.

About Mezeo Software
Mezeo is the industry’s leading provider of a deployable platform for cloud storage. Service-enabled, the Mezeo platform is easy to deploy, multi-tenant, highly scalable and secure, with the Mezeo Cloud Storage API and Interoperability API for platform extensibility. With Mezeo, IT Service Providers can rapidly monetize Storage as a Service with a branded offering, and large enterprises can implement a secure, private cloud with clients for the desktop, Web, BlackBerry® and iPhone. Mezeo was named in CRN’s list of the Top 25 Coolest Emerging Vendors of 2010. For more information, visit www.mezeo.com. 

ALISO VIEJO, CA–(Marketwire – October 18, 2010) –  Enclarity Inc., a leading healthcare information solutions company, today announced the addition of ProviderPoint^® Web Services to its portfolio of hosted solutions. ProviderPoint Web Services gives payers an additional option for updating individual provider records in real-time. This Software as a Service (SaaS) solution uses a secure connection between the payer’s and Enclarity’s servers to automatically update one or more records at a time.

“Typically, a health insurance payer submits provider records to Enclarity for data cleaning and augmentation via a regularly scheduled batch process,” said Stephanie Rose-Belcher, vice president of payer solutions, Enclarity. “Using ProviderPoint Web Services, we now can update records on the fly. With our newest solution, customers are able to save time, money and get updates at the speed of their business.”

How it Works
The payer generates a provider output record that needs verification, augmentation and/or correction, and sends the data through Enclarity’s web service technology for processing. Enclarity ProviderPoint processes the record as soon as it is received, and the updated information is returned within seconds to the client’s system. Then, the client’s system applies the verified, corrected data along with augmentation of additional elements to the provider record. To assure speed and quality, Enclarity ProviderPoint Web Services uses system-to-system processing featuring industry-standard Simple Object Access Protocol (SOAP) message that can be uploaded into any application.

For more information about Enclarity ProviderPoint Web Services, listen to our latest podcast or visit our solution page at http://www.enclarity.com/ppws.php.

About Enclarity
Enclarity^® solves healthcare’s provider information problem. The company delivers correct, current and comprehensive provider information solutions by blending thousands of data sources, advanced analytics and healthcare expertise. As a result, its clients improve results in many areas, including claims processing, provider directories, regulatory compliance and market analysis. Named one of the Top 100 private technology companies in North America by Red Herring magazine and awarded the Global Healthcare Information Technology Excellence Award by Frost & Sullivan, Enclarity is headquartered in Aliso Viejo, Calif. For more information, visit www.enclarity.com.

Click here to see all recent news from this company

BOSTON, MA–(Marketwire – October 18, 2010) –  Shareable Ink, the leading provider of enterprise?grade digital pen and paper applications for healthcare, today announced the general availability of its newest solution, Shareable Ink Analytics™ for Anesthesia. The business intelligence module is a valuable extension of Shareable Ink Anesthesia Record™ that automatically extracts clinical, quality, and efficiency?related data from paper anesthesia records. Real?time access to information helps improve outcomes and operations.

Shareable Ink Analytics enables hospitals and groups to analyze 100 percent of charts without labor?intensive manual chart reviews and data extraction. The new solution incorporates dashboards and drill?down reports for a variety of clinical and administrative metrics, including Surgical Care Improvement Project (SCIP) measures, anesthesia turnover times, and on?time case starts. Managers can easily pinpoint areas of improvement and compare performance across facilities and providers by viewing increasingly granular data: from the health system level to individual outliers and cases of interest.

“More than 90 percent of anesthesia recordkeeping is paper?based. As a result, operational data has been traditionally difficult, if not impossible, to aggregate and understand,” said Stephen S. Hau, President and CEO of Shareable Ink. “The Shareable Ink approach enables anesthesia providers to continue their familiar documentation method, while providing all the analytical benefits of electronic data output.”

“With 360 providers in 28 different hospitals and ASCs, Shareable Ink Analytics gives us the ability to instantly review, report, and manage real-time performance,” said Brian Woods, MD, Chief Medical Officer of NorthStar Anesthesia. “From patient clinical outcome measures to OR throughput efficiency assessments, we can now know exactly how we are doing at the enterprise, facility, and individual provider level.”

Shareable Ink Analytics will be featured at the American Society of Anesthesiologists’ Annual Meeting — ANESTHESIOLOGY 2010 — in San Diego from October 16 through October 20. To learn more, please stop by the Shareable Ink booth (#3930).

About Shareable Ink
Shareable Ink helps healthcare organizations of all sizes transition to electronic health records without disruption to workflow or burdensome IT projects. Its software platform incorporates enterprise?grade digital pen and paper technology featuring Anoto functionality. Shareable Ink enables clinicians to continue documenting in the fastest, most natural manner, while populating the EHR with discrete data, as if typed with a keyboard. Built?in analytics give hospitals and practices insight into their operations — from a clinical, quality and efficiency standpoint — all previously inaccessible from traditional paper records. For additional information, visit www.shareableink.com.

DENVER, CO–(Marketwire – October 18, 2010) –  Omni Bio Pharmaceutical, Inc. (“Omni Bio”) (OTCBB: OMBP) today announced that the first patient has been infused in its FDA-cleared Phase I/II human clinical trial of Alpha-1 antitrypsin (“AAT”) in recently diagnosed Type 1 diabetics at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver Anschutz Medical Campus.

The Phase I/II clinical trial is evaluating the potential of AAT to halt or reduce the deterioration of islet beta cells that causes Type 1 diabetes. While Type 1 diabetics will experience islet beta cell destruction, the trial evaluates whether AAT treatment may help stop the course of disease in newly diagnosed diabetics who may have remaining islet beta cells.

AAT is an FDA-approved, off-patent drug with an almost 20-year safety track record as an approved treatment in the approximately $400 million market for emphysema in AAT deficient patients. Omni Bio believes that the market opportunity for the use of AAT in treating Type 1 diabetes may exceed the current market.

Dr. Charles A. Dinarello, Acting Chief Executive Officer of Omni Bio, stated, “Following promising preclinical evidence of AAT in Type 1 diabetes, we filed with the FDA to move right into a Phase I/II clinical trial in newly diagnosed Type 1 diabetic patients. We are encouraged by the agency’s clearance to advance from the preclinical stage into actual patients, and the initial patient infusion is a major milestone for Omni Bio. If AAT is effective in disrupting the deterioration of the islet beta cells, we believe that we may be able to expedite our time to market in Type 1 diabetes, given the significance of the unmet medical need and the supportive safety track record of AAT in its currently approved indication.”

Dr. Dinarello continued, “Type 1 diabetes is a large and attractive market for Omni Bio, and we believe that our method of use patent applications surrounding AAT further position us to capitalize on this opportunity to deliver shareholder value while improving treatment for up to 20,000 Type 1 diabetics diagnosed in the U.S. each year.”

About the Phase I/II Trial
The FDA-cleared Phase I/II human clinical trial of AAT in recently diagnosed Type 1 diabetics is underway at the Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver Anschutz Medical Campus. Patients will receive an eight-week treatment course of AAT infusions, followed by two years of monitoring. Targeted enrollment is initially 15 patients, and may be expanded to up to 50 patients pending positive data in critical measurements.

About AAT in Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the immune system attacks insulin-producing beta cells in the pancreas, which are necessary for the body to maintain proper blood glucose levels. Not all beta cells are typically destroyed at the time of diagnosis, and between 15-40% remain healthy and able to produce insulin. Preserving these remaining beta cells is the goal of AAT therapy in Type 1 diabetics, as their ability to naturally produce even small amounts of insulin can improve blood sugar control, simplify daily management of diabetes, and reduce the risk of long term complications.

About Omni Bio Pharmaceutical, Inc.
Omni Bio Pharmaceutical, Inc. (www.omnibiopharma.com) is an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential. Omni Bio’s core technology and pipeline are based on issued and pending patents licensed from the University of Colorado Denver (“UCD”) and a privately held corporation surrounding the broader therapeutic potential of currently marketed therapies. One of Omni Bio’s lead development programs is evaluating an FDA-approved, off-patent drug, AAT, for the treatment of Type 1 diabetes. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of bacterial and viral disorders, biohazards, diabetes and transplant rejection.

Omni Bio is led by Acting CEO Dr. Charles Dinarello, Professor of Medicine in the Division of Infectious Diseases at UCD. Dr. Dinarello is considered a founding father of cytokine biology. For additional information, please visit www.omnibiopharma.com.

Forward-Looking Statements
Some of the statements made in this press release are forward-looking statements that reflect management’s current views and expectations with respect to future events, including the clinical trial. These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements. These risks and uncertainties are based on a number of factors, including but not limited to the business risks disclosed in our SEC filings, especially the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2010. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

MISSION, KS–(Marketwire – October 18, 2010) –  (Family Features) Tooth enamel is the hard, outer layer of the tooth that helps protect the tooth from extreme temperatures and the erosive effects of acids.

At times, enamel gets stained and weakened by things you consume such as coffee, tea, fruit juice, soda, wine or cigarettes. Fortunately, there are things you can do to help keep your smile white and your enamel strong.

• Floss and brush daily with a fluoride toothpaste.
• See a dentist every six months for a cleaning and checkup.
• Reduce your intake of highly acidic foods and drinks or rinse with clear water after eating or drinking these things.

Now, Arm & Hammer offers a way to whiten your teeth and strengthen your enamel conveniently and inexpensively. New Arm & Hammer Whitening Booster Plus Enamel Strengthening is designed to provide safe, effective whitening and enamel strengthening without adding an extra step to your oral-care routine. Simply apply over your favorite fluoride toothpaste and brush as normal. Featuring a peroxide formula with Liquid Calcium, this provides teeth with daily whitening and enamel strengthening when used as directed.

Taking good care of your teeth with healthy habits and easy-to-maintain routines will help keep your smile strong and vibrant.

MISSION, KS–(Marketwire – October 18, 2010) – (Family Features) Only about a third of American women are meeting their fruit and vegetable intake recommendations, according to the Centers for Disease Control and Prevention. And that means they are likely missing out on potentially important breast and ovarian health benefits. Along with vitamins, minerals and fiber, fruits and vegetables contain a type of phytonutrient called carotenoids, which research suggests help support women’s health including breast and ovarian health. 

Based on a new report called America’s Phytonutrient Report: Women’s Health by Color, older women have total carotenoid intakes 20 percent greater than younger women after accounting for differences in caloric intake. Similar to the original America’s Phytonutrient Report: Quantifying the Gap which found that on average eight out of 10 American adults are falling short on phytonutrient consumption, the new report revealed a troubling shortfall, this time among women and carotenoids. America’s Phytonutrient Reports are released by The Nutrilite Health Institute, a worldwide collaboration of experts who are dedicated to helping people achieve optimal health — through research, education, and practical, personalized solutions. Nutrilite is the world’s leading brand of vitamin, mineral, and dietary supplements, based on 2008 sales.

Carotenoids are compounds that give fruits and vegetables their vibrant colors, which research suggests may offer breast, ovarian and other health benefits for women. Using NHANES energy-adjusted data to compare the diets of women 45 years and older with those younger, the report finds that many women of all ages lack carotenoid-rich foods in their diet, but the relative magnitude of the “carotenoid gap” is greater among women less than 45 years old as compared to older women.

“This points to a troubling phenomenon where younger women may be missing some of the benefits of consuming more carotenoid rich fruits and vegetables, and yet calorie for calorie, older women are eating more of these important nutrients,” said Keith Randolph, Ph.D., Technology Strategist for Nutrilite. 

Powering Up Produce
Choosing to increase the amount of the fruit and vegetables richest in carotenoids is important for long-term preventative health among women. While foods like spinach, tomatoes and carrots are certainly part of a healthy diet, there are opportunities for women to choose a wider variety of produce.

“It’s concerning that so many American women lack a variety of carotenoid-rich foods in their regular diets,” says Amy Hendel, Nutrilite’s Phytonutrient Coach. “By selecting the most carotenoid-rich produce choices, women can purposefully increase their carotenoid and phytonutrient intakes which can impact health significantly as they age.”

Hendel, a registered physician assistant and health/wellness expert, offers these easy substitutions to “power up” your plate and add new flavors to your meal plan:

Green: A serving of cooked kale provides triple the amount of lutein/zeaxanthin as a serving of raw spinach.
Red: A serving of guava delivers more than one and a half times the lycopene in a raw tomato.
Yellow/Orange:

• A serving of sweet potatoes has nearly double the beta-carotene as a serving of carrots.
• A serving of carrots delivers four times the amount of alpha-carotene as a serving of winter squash.
• A serving of fresh papaya has roughly 10 times the beta-cryptoxanthin found in an orange.

Hendel adds, a good goal for most individuals is to consume 10 servings of fruits and vegetables daily, with an emphasis on quality, not just quantity. If this proves challenging, consider a natural, plant-based dietary supplement which includes phytonutrients such as carotenoids.

For more information about Nutrilite Nutritional Supplements and to get more practical tips, visit www.nutrilite.com/color.

MISSION, KS–(Marketwire – October 18, 2010) – (Family Features) As expectant and new moms know, having a baby is one of the most wonderful experiences, but it can also be overwhelming. First-time mothers and veteran moms alike have questions about keeping their babies safe and healthy. They’re eager to learn about important areas such as nutrition, immunization, and safe sleep. 

To address their questions and concerns, the National Healthy Mothers, Healthy Babies Coalition (HMHB) developed text4baby. This free mobile educational service promotes a healthy pregnancy and a healthy start in life for all babies.

With more than 1.3 trillion text messages sent and received in the U.S. in 2009, it makes sense to deliver vital health information through mobile technology. Currently in the United States, more than 500,000 babies — 1 in every 8 — are born prematurely. An estimated 28,000 children die before their first birthday, a rate among the highest in the industrialized world. Premature infants come into the world with unique health needs that can mean lifelong challenges. Text4baby helps to address these issues by allowing timely and useful information to be distributed to help give babies the best possible start in life. 

While not everyone has access to the internet, 90 percent of Americans have a mobile phone. Text messaging is soaring in popularity and can be especially helpful in reaching first-time mothers in typically underserved populations.

How It Works
By texting BABY (or BEBE for Spanish) to 511411, a woman will be signed up to receive three free text messages each week that are timed to her due date or baby’s date of birth. These messages focus on a variety of topics critical to maternal and child health, including birth defects prevention, immunization, nutrition, seasonal flu, mental health, oral health, and safe sleep. Text4baby text messages also connect women to prenatal and infant care services and other resources.

Wireless carriers are waiving text messaging fees for the initiative, so enrollees opting in to receive text messages will incur no charges. Even users without a text messaging plan or limited texting per month will receive these messages for free.

To date, text4baby has sent more than five million English and Spanish text messages to more than 83,000 pregnant and new mothers. According to text4baby enrollment numbers, 96 percent of participants would recommend the service to a friend. 67 percent of the enrollees are receiving information about pregnancy, while the remaining 33 percent are getting information about newborns. 

“For those of us dedicated to health education, knowing that text4baby messages are reaching the women who are most in need of them is incredibly powerful and exciting,” said Judy Meehan, CEO of the National Healthy Mothers, Healthy Babies Coalition. “Thanks to our partnership with CTIA-The Wireless Foundation and the mobile carriers, more than 5 million valuable health messages have been put in the hands of thousands of pregnant women since our February 4 launch.”

Text4baby is made possible through a public-private partnership that includes more than 350 organizations. The program’s founding partners include CTIA-The Wireless Foundation.

For more information, or to sign-up to receive the free text messages, visit www.text4baby.org.

MENLO PARK, CA–(Marketwire – October 18, 2010) –  Depomed, Inc. (NASDAQ: DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the 17^th Annual Meeting of NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 9:30 am EST, and at the Oppenheimer 21^st Annual Healthcare Conference on Wednesday, November 3, 2010 at 2:45 pm EST, both in New York City.

The company will be webcasting its presentation and interested parties can access the live or archived presentation for up to 90 days on the company’s website at www.depomed.com.

About Depomed
Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Abbott Products Inc. A New Drug Application for DM-1796 was accepted by the FDA in the second quarter of 2010. Product candidate Serada^® is in Phase 3 clinical development for menopausal hot flashes. GLUMETZA^® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform^® drug delivery technology, which is designed to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Additional information about Depomed may be found on its website, http://www.depomed.com.

CENTERVILLE, MA–(Marketwire – October 18, 2010) –  UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is pleased to announce that it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication “Public Service Review.” In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement.

The Public Service Review features contributors that include UK and foreign ministers, senior civil servants, experts and academics discussing the latest initiatives and projects along with case studies and comments on best practices affecting public sector initiatives worldwide.

“The spread of airborne bacteria and infectious diseases in the United Kingdom, in some areas, is reaching epidemic levels,” said Jack Lennon, President of UV Flu Technologies. “There is more than a 10% risk of becoming infected by HAI’s, or hospital associated infections, in many of the medical facilities in the United Kingdom, making Infection Control a much more visible issue than it is in this country. Being selected for inclusion by the ‘Review’ as the only laboratory tested device capable of killing these bacterial superbugs is a distinct honor.”

Mr. Lennon continued to say, “There is a great deal of attention in the UK, and in the United States, on the spread of MRSA, a bacteria resistant to antibiotics and estimated to kill tens of thousands of people every year, and in many instances affects people who have been in a medical facility. In fact, over the last 4 weeks an outbreak of Legionnaires Disease in South Wales garnered international attention as three deaths were reported, and a number of people were stricken. The world believed Legionnaires to no longer pose a threat, but experts believe it kills thousands of people yearly through improper diagnosis as pneumonia. The ViraTech UV-400 cost effectively and efficiently kills these airborne bacterial strains, and it was this that led to our inclusion in this particular issue.”

Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC’s, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription. 

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
—————————–
John J. Lennon, President & CEO

Click here to see all recent news from this company